Predicting Response to Standardized Pediatric Colitis Therapy (PROTECT)
Multicenter Open-label Study Evaluating the Safety and Efficacy of Standardized Initial Therapy Using Either Mesalamine or Corticosteroids Then Mesalamine to Treat Children and Adolescents With Newly Diagnosed Ulcerative Colitis.
Sponsor: Connecticut Children's Medical Center
A PHASE4 clinical study on Ulcerative Colitis, this trial is completed. The trial is conducted by Connecticut Children's Medical Center and has accumulated 10 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Oct 2019 — Jan 2021 [monthly]
Completed PHASE4
-
Sep 2019 — Oct 2019 [monthly]
Completed PHASE4
▶ Show 5 earlier versions
-
Nov 2018 — Sep 2019 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Jun 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE4
-
Jul 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE4
-
Feb 2017 — Jul 2017 [monthly]
Active Not Recruiting PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE4
First recorded
Jul 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Connecticut Children's Medical Center
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
For direct contact, visit the study record on ClinicalTrials.gov .